COMPANY NEWS

Eight New MyoStrain Posters and Presentations Presented at ESC Congress in Paris 2019

By Myocardial Solutions

September 5, 2019

PARIS, FRANCE, September 5, 2019 – Last weekend, the Myocardial Solutions (MSI) team attended the European Society of Cardiology (ESC) Congress 2019 to further the discussion of MyoStrain as a unique clinical tool for helping physicians proactively detect, monitor and manage heart failure. The ESC Congress took place from August 31st to September 4th and was held at the Paris Expo Porte de Versailles in Paris, France.

During the event, MyoStrain was featured in six new posters and two speaker presentations: a podium presentation by Professor Sebastian Kelle of Berlin Heart Institute and a rapid-fire presentation by Marien Hospital Head of Cardiac Imaging Dr. Moritz Montenbruck.

Posters and presentation topics covered:

  • Early detection of heart failure in asymptomatic patients using MyoStrain
  • Comparing MyoStrain versus global longitudinal strain (GLS) and ejection fraction (EF) in early detection of heart failure progression
  • Comparing MyoStrain with EF in early detection of subclinical cardiac dysfunction
  • Early detection of heart failure using MyoStrain mobile testing
  • MyoStrain as a tool to analyze myocardial deformation in chest pain patients
  • Comparing MyoStrain versus echocardiography (ECHO) in early detection of cardiotoxicity during oncology treatment
  • MyoStrain as a tool to help manage cardioprotective therapy in cardiotoxic patients
  • Characterization of tissue in patients with Wilsons’s disease using MyoStrain and CMR EF

Links to the posters are provided below:

1. Cardiac Tissue Characterization in Patients with Wilsons’s Disease using Cardiac Magnetic Resonance Imaging

Citation: Heins J et al. Cardiac Tissue Characterization in Patients with Wilsons’s Disease using Cardiac Magnetic Resonance Imaging. ESC Congress 2019.

2. Early detection of heart failure using mobile CMR and telemedicine

Citation: Kelle S et al. Early detection of heart failure using mobile CMR and telemedicine. ESC Congress 2019.

3. CMR Fast-SENC segmental intramyocardial LV strain detects heart disease progression based on ACC/AHA Heart Failure stage before global longitudinal strain or ejection fraction

Citation: Montenbruck, M et al. CMR Fast-SENC segmental intramyocardial LV strain detects heart disease progression based on ACC/AHA Heart Failure stage before global longitudinal strain or ejection fraction. ESC Congress 2019.

4. Fast-SENC quantifies segmental right ventricular intramyocardial strain to assess subclinical RV dysfunction prior to changes in RV ejection fraction

Citation: Montenbruck, M et al. Fast-SENC quantifies segmental right ventricular intramyocardial strain to assess subclinical RV dysfunction prior to changes in RV ejection fraction. ESC Congress 2019.

5. Segmental intramyocardial CMR Fast-SENC objectively quantifies cardiac dysfunction that causes symptoms based on NYHA classification before global longitudinal strain or ejection fraction

Citation: Montenbruck, M et al. Segmental intramyocardial CMR Fast-SENC objectively quantifies cardiac dysfunction that causes symptoms based on NYHA classification before global longitudinal strain or ejection fraction. ESC Congress 2019.

6. Analysis of myocardial deformation using fSENC-CMR on patients with chest pain

Citation: Siry, D et al. Analysis of myocardial deformation using fSENC-CMR on patients with chest pain. ESC Congress 2019.

7. CMR Fast-SENC Intramyocardial LV & RV Segmental Strain Detects Cardiotoxicity during Oncology Treatment and Impact of Cardioprotection Therapy before Echocardiography

Citation: Steen, H et al. CMR Fast-SENC Intramyocardial LV & RV Segmental Strain Detects Cardiotoxicity during Oncology Treatment and Impact of Cardioprotection Therapy before Echocardiography. ESC Congress 2019.

8. CMR Fast-SENC Intramyocardial LV & RV Segmental Strain Helps Manage Cardioprotective Therapy in Patients Exhibiting Cardiotoxicity during Cancer Treatment

Citation: Steen, H et al. CMR Fast-SENC Intramyocardial LV & RV Segmental Strain Helps Manage Cardioprotective Therapy in Patients Exhibiting Cardiotoxicity during Cancer Treatment. ESC Congress 2019.

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain® has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.